FAS proposals on indexing prices for the life-saving and essential medicinal drugs in the lower price segment

Due to numerous reports in mass media FAS would like to inform that in November 2015 the Federal Antimonopoly Service (FAS Russia) indeed submitted a proposal to the Government of the Russian Federation to support domestic pharmaceutical manufacturers in the part of one-time indexing of prices for the drugs included in the list of life-saving and essential medicinal drugs with the registered price for up to 50 RUB.

Based on the outcome of the discussion, the Government made a decision to look into the issue of subsidizing manufacturers of life-saving and essential medicinal drugs in the lower price segment.

Therefore, at the moment FAS proposal on one-time indexing of previously registered prices (up to 50 RUB) for life-saving and essential medicinal drugs for a common fixed value is no longer valid.

Currently FAS, jointly with the authorized federal executive bodies, is addressing the issue of subsidizing manufacturers of life-saving and essential medicinal drugs under the frame of the instructions issued by the Government.

In the FAS opinion, granting subsidies to drug manufacturers must be accompanied with the guarantee of preserving production of such medicinal drugs in the required volume.